Gene Therapy: Vector Design and Current Challenges

  • Elizabeth G. Nabel
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 193)


Gene transfer is an approach to the treatment of human diseases based on the delivery and expression of genetic material into somatic cells. Gene delivery can be achieved in vivo through direct introduction into cells or ex vivo through manipulation of cells in culture. In this sense, gene therapy is a new form of drug delivery, in which the drug is recombinant protein synthesized by transduced cells. Gene therapy can be viewed as an extension of conventional medical therapies in which the genetic material is the therapeutic agent. Gene therapy is being applied to many human diseases, and it offers the potential to cure diseases, either as a single treatment modality or as an adjuvant to existing treatments. However, gene therapy is still in its infancy, and many of these promises have not yet been fulfilled.


Cystic Fibrosis Gene Therapy Gene Delivery Peripheral Artery Disease Nonviral Vector 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nabel EG. Gene therapy for cardiovascular diseases. Circulation 91:541, 1995.PubMedGoogle Scholar
  2. 2.
    Nabel EG, Yang Z, Plautz G, Forough R, Zhan X, Haudenschild CC, Maciag T, Nabel GJ. Recombinant fibroblast growth factor-1 promotes intimai hyperplasia and angiogenesis in arteries in vivo. Nature 362:844, 1993.PubMedCrossRefGoogle Scholar
  3. 3.
    von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 92:1137, 1995.PubMedCrossRefGoogle Scholar
  4. 4.
    Geary RL, Clowes AW, Lau S, Vergel S, Dale DC, Osborne WR. Gene transfer in baboons using prosthetic vascular grafts seeded with retrovirally transduced smooth muscle cells: A model for local and systemic gene therapy. Hum Gene Ther 5:1211, 1994.PubMedGoogle Scholar
  5. 5.
    Chang MW, Barr E, Seltzer J, Jiang J-Q, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders using a constitutively active form of Rb. Science 267:518, 1995.PubMedCrossRefGoogle Scholar
  6. 6.
    Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J, Rossow S, Rosenfield K, Weir L, Brogi E, Shainfield R. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease [news]. Circulation 91:2687, 1995.PubMedGoogle Scholar
  7. 7.
    Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF. Clinical evidence of angiogenesis after arterial gene transfer of ph VEGF 165 in patient with ischaemic limb. Lancet 348:370, 1996.PubMedCrossRefGoogle Scholar
  8. 8.
    Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 249:1285, 1990.PubMedCrossRefGoogle Scholar
  9. 9.
    Miller AD. Retroviral vectors. Curr Top Microbiol 158:1, 1992.Google Scholar
  10. 10.
    Nabel EG. Vectors for gene therapy. In Current Protocols in Human Genetics. New York: John Wiley, 1996: 12.0.1.Google Scholar
  11. 11.
    Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407, 1994.PubMedCrossRefGoogle Scholar
  12. 12.
    Yang Y, Nunes FA, Berencsi K, Gonczol E. Engelhardt JF, Wilson JM. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet 7:362, 1994.PubMedCrossRefGoogle Scholar
  13. 13.
    Stephan D, Yang ZY, San H, Simari RD, Wheeler CJ, Feigner PL, Gordon D, Nabel GJ, Nabel EG A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo. Hum Gene Ther 7:1803, 1996.PubMedCrossRefGoogle Scholar
  14. 14.
    Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/ plasmin system. Thromb Haemost 74:429, 1995.PubMedGoogle Scholar
  15. 15.
    Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nature Med 2:293, 1996.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Elizabeth G. Nabel

There are no affiliations available

Personalised recommendations